Biogen says it will start delivering Alzheimer's drug in US in two weeks

Drug is the first treatment to target a likely underlying cause of Alzheimer's, sticky deposits of a protein called amyloid-beta, and the first to be approved in decades

Biogen once had a link with former Irish-based drugs firm Elan.

Biogen, the US drugs firm that won approval from the Food and Drugs Administration for its Alzheimer's drug, said it expects to start delivering to US heathcare centres for the intravenous infusion in two weeks. 

Its Aduhelm drug is the first treatment to target a likely underlying cause of Alzheimer's disease, sticky deposits of a protein called amyloid-beta, and the first to be approved in decades.